Clinical Advisor42m
Qfitlia, a Novel Treatment for Hemophilia A or B, Gets FDA Approval
Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
Zacks Investment Research on MSN5h
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure
This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...
Pharmaceutical Technology11h
FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditions
Sanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug Administration’s (FDA) orphan drug ...